Generic placeholder image

Current Pharmaceutical Biotechnology

Editor-in-Chief

ISSN (Print): 1389-2010
ISSN (Online): 1873-4316

Research Article

Biodistribution and Tumor Targeted Accumulation of Anti-CEA-loaded Iron Nanoparticles

In Press, (this is not the final "Version of Record"). Available online 06 February, 2024
Author(s): Thais Silva Correa, William Gustavo Lima, Aline Beatriz do Couto Campos, Alexsandro Sobreira Galdino*, Emilia Celma de Oliveira Lima, Valbert Nascimento Cardoso, Simone Odília Antunes Fernandes and Mariana Campos-da-Paz
Published on: 06 February, 2024

DOI: 10.2174/0113892010268872240104114444

Price: $95

conference banner
Abstract

Introduction: Active targeting of tumors by nanomaterials favors early diagnosis and the reduction of harsh side effects of chemotherapeuticals.

Method: We synthesized magnetic nanoparticles (64 nm; -40 mV) suspended in a magnetic fluid (MF) and decorated them with anti-carcinoembryonic antigen (MFCEA; 144 nm; -39 mV). MF and MFCEA nanoparticles were successfully radiolabeled with technetium–99m (99mTc) and intravenously injected in CEA-positive 4T1 tumor-bearing mice to perform biodistribution studies. Both 99mTc-MF and 99mTc-MFCEA had marked uptake by the liver and spleen, and the renal uptake of 99mTc-MFCEA was higher than that observed for 99mTc-MF at 20h. At 1 and 5 hours, the urinary excretion was higher for 99mTc-MF than for 99mTc-MFCEA.

Results: These data suggest that anti-CEA decoration might be responsible for a delay in renal clearance. Regarding the tumor, 99mTc-MFCEA showed tumor uptake nearly two times higher than that observed for 99mTc-MFCEA. Similarly, the target-nontarget ratio was higher with 99mTc-MFCEA when compared to the group that received the 99mTc-MF.

Conclusion: These data validated the ability of active tumor targeting by the as-developed antiCEA loaded nanoparticles and are very promising results for the future development of a nanodevice for the management of breast cancer and other types of CEA-positive tumors.

Keywords: breast cancer, magnetic nanoparticles, targeting, carcinoembryonic antigen, nanotechnology, theranostic


Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy